Abstract: A mobile processing laboratory (MPL) is provided, configured for facilitating performing therewithin a cell therapy process. The MPL comprises a portable enclosure; one or more pieces of laboratory equipment for carrying out the cell therapy process and being housed within the enclosure; a plurality of sensors, each configured to measure information regarding the environment, cellular material of the process, and/or one of the pieces of laboratory equipment; and a computer system configured for management of the cell therapy process. The computer system is configured to facilitate collecting data from the sensors, and to optimize one or more activities associated with performance of the cell therapy process based on data collected from one or more other MPLs configured for performing therewithin substantially the same cell therapy process.

Abstract: The present disclosure provides methods for prophylactically treating a subject for viral infections comprising topically administering a ranpirnase composition. The disclosure also provides compositions that could be used for prophylactic treatment.

Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.

Abstract: Provided an artificial bioxome particle comprising a cell membrane component and designed to undergo fusion with a target cell, wherein said bioxome particle is engineered to carry a cargo comprising at least one predetermined active molecule; and wherein said cargo can be released into the target cell after the fusion of the bioxome particle with the target cell; and wherein the cell membrane component is derived from a selected cellular or extracellular source; methods of use of the particles; and processes for manufacturing thereof.

Abstract: An experiment has shown that ranpirnase is a microbicide. It is believed that topical application of a topical pharmaceutical composition consisting essentially of a prophylactically effective concentration of an enzymatically-active ribonuclease (e.g. ranpirnase) and a viscous vehicle that does not unacceptably interfere with the enzymatic activity (e.g. K-Y® Brand Jelly) will prophylactically protect an individual from a sexually-transmitted viral infection, particularly HIV. It is also believed that e.g. ranpirnase can be delivered to tissues of an individual who is to be prophylactically protected against viral infections by transfecting ranpirnase DNA into human microbiota and exposing the individual to the thus-modified human microbiota. It is also believed that ranpirnase can be delivered to a woman who is to be prophylactically protected against a sexually-transmitted viral infection by use of an intravaginal ring that has been impregnated with ranpirnase.